Compile Data Set for Download or QSAR
Report error Found 210 Enz. Inhib. hit(s) with Target = 'Non-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A]'
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493100BDBM493100(US10981911, Example 40 | 1-((1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 0.300nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493065BDBM493065(US10981911, Example 6 | 2-((1r,4r)-4-(2-(2-Oxo-2-(...)
Affinity DataIC50: 0.400nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493101BDBM493101(US10981911, Example 41 | 2-((1r,4r)-4-(2-(Thiazol-...)
Affinity DataIC50: 0.600nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493067BDBM493067(US10981911, Example 8 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 0.700nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493066BDBM493066(US10981911, Example 7 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 0.900nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387823BDBM387823(US10294226, Compound Ex. 6 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 1.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493281BDBM493281(US10981911, Example 201 | 2-(1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 1.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493070BDBM493070(US10981911, Example 11 | 2-((1r,4r)-4-(2-(Oxazol-4...)
Affinity DataIC50: 1.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493269BDBM493269(US10981911, Example 198 | 2-(1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 1.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493076BDBM493076(US10981911, Example 17A | (E)-N-((1-((1r,4r)-4-(Cy...)
Affinity DataIC50: 1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493071BDBM493071(US10981911, Example 12 | 2-((1r,4r)-4-(2-(2-(4-Hyd...)
Affinity DataIC50: 1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493156BDBM493156(US10981911, Example 95 | (EZ)—N-((1-((1r,4r)-...)
Affinity DataIC50: 1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387828BDBM387828(US10294226, Compound Ex. 11 | 2-(1-((1r,4r)-4-(Cya...)
Affinity DataIC50: 1.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387819BDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 1.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493068BDBM493068(US10981911, Example 9 | 2-((1r,4r)-4-(2-(1H-1,2,4-...)
Affinity DataIC50: 1.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493090BDBM493090(US10981911, Example 30 | N-((1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 1.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493080BDBM493080(US10981911, Example 20 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 1.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493096BDBM493096(US10981911, Example 36 | N-((1H-imidazol-2-yl)meth...)
Affinity DataIC50: 2.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387821BDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 2.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493150BDBM493150(US10981911, Example 90 | 2-((1r,4r)-4-(2-(2-Oxo-2-...)
Affinity DataIC50: 2.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 50527404BDBM50527404(CHEMBL4514898 | US10981911, Example 62)
Affinity DataIC50: 2.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493146BDBM493146(US10981911, Example 86 | N-((1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 2.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 50527405BDBM50527405(CHEMBL4456630 | US10981911, Example 26)
Affinity DataIC50: 2.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493092BDBM493092(US10981911, Example 32 | N-((3R,5R)-Adamantan-1-yl...)
Affinity DataIC50: 2.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493126BDBM493126(US10981911, Example 66 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 2.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493073BDBM493073(US10981911, Example 14 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 2.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493221BDBM493221(US10981911, Example 156 | (3R,5R,7R)—N-((1-((...)
Affinity DataIC50: 2.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493077BDBM493077(US10981911, Example 17B | (Z) N-((1-((1r,4r)-4-(Cy...)
Affinity DataIC50: 2.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387825BDBM387825(US10294226, Compound Ex. 8 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 3.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493072BDBM493072(US10981911, Example 13 | 2-Cyano-N-((1-((1r,4r)-4-...)
Affinity DataIC50: 3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493084BDBM493084(US10981911, Example 24 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493131BDBM493131(US10981911, Example 71 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 50527409BDBM50527409(CHEMBL4447497 | US10981911, Example 58)
Affinity DataIC50: 3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493120BDBM493120(US10981911, Example 60 | 2-((1r,4r)-4-(2-(1H-Pyraz...)
Affinity DataIC50: 3.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 50527410BDBM50527410(CHEMBL4439418 | US10981911, Example 57)
Affinity DataIC50: 3.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493088BDBM493088(US10981911, Example 28 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 3.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493083BDBM493083(US10981911, Example 23 | N-(4-Cyanobicyclo[2.2.1]h...)
Affinity DataIC50: 3.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493081BDBM493081(US10981911, Example 21 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 3.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493075BDBM493075(US10981911, Example 16 | 2-((1r,4r)-4-(2-(2H-1,2,3...)
Affinity DataIC50: 3.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493091BDBM493091(US10981911, Example 31 | 2-((1r,4r)-4-(2-(4-Chloro...)
Affinity DataIC50: 3.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493127BDBM493127(US10981911, Example 67 | 2-((1r,4r)-4-(2-(2-(1,1-D...)
Affinity DataIC50: 3.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493089BDBM493089(US10981911, Example 29 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 3.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 50527407BDBM50527407(CHEMBL4582390 | US10981911, Example 33)
Affinity DataIC50: 3.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387822BDBM387822(US10294226, Compound Ex. 5 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493140BDBM493140(US10981911, Example 80 | 1-((1r,4r)-4-(Cyanomethyl...)
Affinity DataIC50: 4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493074BDBM493074(US10981911, Example 15 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387824BDBM387824(US10294226, Compound Ex. 7 | N-(2-Cyano-2-methylpr...)
Affinity DataIC50: 4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493114BDBM493114(US10981911, Example 54 | 4-(2-(1-((1r,4r)-4-(Cyano...)
Affinity DataIC50: 4.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493109BDBM493109(US10981911, Example 49 | 2-((1r,4r)-4-(2-(2-Oxo-2-...)
Affinity DataIC50: 4.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493097BDBM493097(US10981911, Example 37 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 4.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

Displayed 1 to 50 (of 210 total ) | Next | Last >>
Jump to: